International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency

被引:162
作者
Lichtman, Stuart M.
Wildiers, Hans
Launay-Vacher, Vincent
Steer, Christopher
Chatelut, Etienne
Aapro, Matti [1 ]
机构
[1] Doyen IMO Clin Genolier, CH-1272 Genolier, Switzerland
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[4] Hop La Pitie Salpetriere, Paris, France
[5] Univ Toulouse 3, F-31062 Toulouse, France
[6] Inst Claudius Regaud, Toulouse, France
关键词
clinical practice recommendations; elderly; cancer; renal insufficiency; creatinine clearance; serum creatinine; dosing adjustments;
D O I
10.1016/j.ejca.2006.11.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A SIOG taskforce was formed to discuss best clinical practice for elderly cancer patients with renal insufficiency This manuscript outlines recommended dosing adjustments for cancer drugs in this population according to renal function. Dosing adjustments have been made for drugs in current use which have recommendations in renal insufficiency and the elderly, focusing on drugs which are renally eliminated or are known to be nephrotoxic. Recommendations are based on pharmacokinetic and/or pharmacodynamic data where available. The taskforce recommend that before initiating therapy, some form of geriatric assessment should be conducted that includes evaluation of comorbidities and polypharmacy, hydration status and renal function (using available formulae). Within each drug class, it is sensible to use agents which are less likely to be influenced by renal clearance. Pharmacokinetic and pharmacodynamic data of anticancer agents in the elderly are needed in order to maximise efficacy whilst avoiding unacceptable toxicity. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:14 / 34
页数:21
相关论文
共 266 条
  • [41] PLATINUM KINETICS IN PATIENTS TREATED WITH CIS-DICHLORODIAMMINE PLATINUM(II)
    BUICE, RG
    SOLOWAY, MS
    [J]. THERAPEUTIC DRUG MONITORING, 1982, 4 (03) : 293 - 296
  • [42] CALVERT AH, 1977, CANCER TREAT REP, V61, P1647
  • [43] CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION
    CALVERT, AH
    NEWELL, DR
    GUMBRELL, LA
    OREILLY, S
    BURNELL, M
    BOXALL, FE
    SIDDIK, ZH
    JUDSON, IR
    GORE, ME
    WILTSHAW, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) : 1748 - 1756
  • [44] CAMAGGI CM, 1985, DRUG EXP CLIN RES, V11, P285
  • [45] Gemcitabine/carboplatin in advanced urothelial cancer
    Carles, J
    Nogué, M
    [J]. SEMINARS IN ONCOLOGY, 2001, 28 (03) : 19 - 24
  • [46] Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function
    Carles, J
    Nogué, M
    Domènech, M
    Pérez, C
    Saigí, E
    Villadiego, K
    Guasch, I
    Ibeas, R
    [J]. ONCOLOGY, 2000, 59 (01) : 24 - 27
  • [47] Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy:: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival
    Carlson, K
    [J]. BONE MARROW TRANSPLANTATION, 2005, 35 (10) : 985 - 990
  • [48] Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure - a retrospective analysis and recommendations for dose adjustment
    Carlson, K
    Hjorth, M
    Knudsen, LM
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (05) : 631 - 635
  • [49] Carlson L, 1998, CANCER CHEMOTH PHARM, V41, P140
  • [50] High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease
    Casserly, LF
    Fadia, A
    Sanchorawala, V
    Seldin, DC
    Wright, DG
    Skinner, M
    Dember, LM
    [J]. KIDNEY INTERNATIONAL, 2003, 63 (03) : 1051 - 1057